Inhibition of antigen-induced airway hyperresponsiveness by ultralow molecular-weight heparin

Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):887-93. doi: 10.1164/ajrccm.157.3.9708027.

Abstract

Unfractionated heparin (UF-heparin) has been shown to prevent antigen-induced airway hyperresponsiveness (AHR), but it is ineffective when administered after the antigen challenge. We hypothesized that the failure of UF-heparin to modify postantigen AHR might depend on molecular weight. We therefore studied the effects of UF-heparin and three low-molecular-weight heparin fractions (medium-molecular-weight heparin [MMWH]; low-molecular-weight heparin [LMWH]; and ultralow-molecular-weight heparin [ULMWH]) on antigen-induced AHR and histamine release in bronchoalveolar lavage fluid (BALF). Specific lung resistance (SRL) was measured in 20 allergic sheep before, immediately after, and up to 2 h after challenge with Ascaris suum antigen. Airway responsiveness was expressed as the cumulative provocative dose of carbachol, in breath units, that increased SRL by 400% (PD400). PD400 was determined before and 2 h after antigen, both without and after treatment with aerosolized UF-heparin (1,000 U/kg) and various heparin fractions (0.04 mg/kg to 5 mg/kg) administered after the antigen challenge. Inhaled UF-heparin (n = 4), MMWH (n = 4), and LMWH (n = 6) failed to modify postantigen AHR when administered after the challenge. Only ULMWH (n = 6) inhibited postantigen AHR in a dose-dependent manner (percent protection ranged from 31% to 139%). In eight additional sheep, histamine in BALF was measured with a radioimmunoassay (RIA) before and after the segmental antigen challenge, without and after pretreatment with inhaled UF-heparin, LMWH, or ULMWH. Inhaled UF-heparin and LMWH inhibited antigen-induced histamine release as measured in BALF by 81% and 75%, respectively; whereas ULMWH was ineffective in this respect. We conclude that: (1) modification of antigen-induced AHR by fractionated heparins is molecular-weight dependent; and (2) only ULMWH attenuates AHR when administered after antigen challenge, via an unknown mast-cell-independent action.

MeSH terms

  • Administration, Inhalation
  • Aerosols
  • Airway Resistance / drug effects
  • Animals
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Antigens, Helminth / immunology*
  • Ascaris suum / immunology
  • Bronchial Hyperreactivity / immunology
  • Bronchial Hyperreactivity / prevention & control*
  • Bronchial Provocation Tests
  • Bronchoalveolar Lavage Fluid / chemistry
  • Bronchoconstriction / drug effects
  • Carbachol
  • Dose-Response Relationship, Drug
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Histamine / analysis
  • Histamine Release / drug effects
  • Lung / drug effects
  • Lung / immunology
  • Mast Cells / immunology
  • Molecular Weight
  • Muscarinic Agonists
  • Respiratory Hypersensitivity / immunology
  • Sheep

Substances

  • Aerosols
  • Anticoagulants
  • Antigens, Helminth
  • Heparin, Low-Molecular-Weight
  • Muscarinic Agonists
  • Histamine
  • Carbachol